Sify (Free subscription) | 20/11/2009
ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.
Daily Advance - Business (Free subscription) | 19/11/2009
WALTHAM, Mass. — ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second pote...
Xconomy (Free subscription) | 19/11/2009
Waltham, MA-based ImmunoGen (NASDAQ: IMGN) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen’s technology for linking targeted antibodies to cell-killing agents that make them more potent. ImmunoGen will get $1 million upfront and could receive $34 million worth of milestone payments over time if Amgen is successful [...]
Business Wire (Free subscription) | 19/11/2009
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such license to be taken by Amgen –...
SeekingAlpha ETFs (Free subscription) | 16/11/2009
George Spritzer submits: H&Q Healthcare Investors ( HQH ) appears to a be a decent value now within the closed-end fund universe. It is broadly diversified, and primarily invests in biotechnology, medical devices, pharmaceuticals and medical delivery. It also invests a limited portion of the portfolio in smaller, emerging companies and some restricted securities. In their last SEC filing (as of...
PharmaGossip (Free subscription) | 16/11/2009
THE NEXT time pharmaceutical companies raise dire warnings about federal proposals to measure the cost-effectiveness of their products, they should be required to read the recent study in the New England Journal of Medicine about a kidney drug called Aranesp. For decades, doctors have prescribed this drug or others like it to patients with type 2 diabetes and kidney disease in the belief that the...
The Truth About Obesity (Free subscription) | 14/11/2009
The New York Attorney General’s office announced that New York and 14 other states will sue biotech giant Amgen Inc for allegedly rewarding medical providers with kickbacks if they helped to boost sales of anemia drug Aranesp. See States will sue Amgen Inc about alleged kickbacks to boost Aranesp sales You can reduce anaemia problems by cutting [...]
PharmaGossip (Free subscription) | 14/11/2009
via latimes.com A lawsuit by 15 states alleges that sales representatives of Thousand Oaks-based Amgen encouraged doctors and other healthcare providers to bill insurers for supplies of anemia drug Aranesp that the providers received free from the company. The practice allegedly cost taxpayer-funded Medicaid programs and other insurers millions of dollars in overpayments. The lawsuit against Amgen...
The IN VIVO Blog (Free subscription) | 13/11/2009
Just how big is the $170 million up-front payment that Abbott ponied up for PanGenetics' PG110 anti-NGF antibody yesterday? Absolutely enormous. In fact so far as we can tell, it's the largest up-front payment for a Phase I project, ever (and Phase I isn't even complete yet). Put the payment in the context of today's earn-out heavy, let's-share-the-risk dealmaking climate, where options-to-maybe-consider-licensing-in-the-future...
PR News Wire (Free subscription) | 12/11/2009
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation...
Red Orbit (Free subscription) | 12/11/2009
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A.
Uremic Frost (Free subscription) | 11/11/2009
A study printed in the Journal of the National Cancer Institute has taken a look at cancer patients using erythrocyte stimulating agents (ESA)... and it is not good news for Johnson & Johnson and Amgen. The study examined patient with cancer, not CKD. They evaluated 56,210 patients who were diagnosed with lymphoma, breast cancer, non-small cell lung cancer, or colon cancer over a 10-year period...
PR News Wire (Free subscription) | 11/11/2009
CHICAGO, Nov. 11 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for GE, AMGN, NKE, GMCR, and CDE.
Xconomy (Free subscription) | 11/11/2009
Alder Biopharmaceuticals keeps such a low profile that even after five years in business, few people in Seattle biotech know who they are. That changed yesterday as the private Bothell, WA-based company burst onto the local, and national, biotech scene by striking a deal with Bristol-Myers Squibb that could be worth more than $1 billion [...]
Euro Peloton - Pro Cycling News (Free subscription) | 09/11/2009
The 2009 Amgen Tour of California proved to be a good barometer for who would shine in 2009. Held in February at the beginning of the season, the nine day race was long enough and tough enough to show who would have the chops later in the season. Now scheduled for May, next year's race will be a great indicator for who will be the top favorites at the Tour de France, but the day's of using the AToC...
Videos